Gabriele Elbl
Nessuna posizione attualmente
Profilo
Gabriele Elbl worked as Head-Regulatory Affairs at MorphoSys AG from 2013 to 2018.
Prior to that, she was SVP-Regulatory Affairs & Quality Control at Heidelberg Pharma AG in 2012.
She also served as Vice President-Global Regulatory Affairs at Nordic Nanovector ASA. Elbl holds a doctorate degree from Ludwig-Maximilians-Universität München.
Precedenti posizioni note di Gabriele Elbl
| Società | Posizione | Fine |
|---|---|---|
| MORPHOSYS AG | Consigliere Generale | 01/10/2018 |
| THOR MEDICAL | Consigliere Generale | - |
| HEIDELBERG PHARMA AG | Consigliere Generale | - |
Formazione di Gabriele Elbl
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| HEIDELBERG PHARMA AG | Health Technology |
| MORPHOSYS AG | Health Technology |
| Aziende private | 1 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
- Borsa valori
- Insiders
- Gabriele Elbl
